Literature DB >> 26122306

Minnelide, a novel drug for pancreatic and liver cancer.

Sulagna Banerjee1, Ashok Saluja2.   

Abstract

BACKGROUND: Pancreatic cancer is the 10th leading cause of all new cancer cases for men and the fourth leading cause of death across genders, having very poor prognosis and survival rates. The current standard of care Gemcitabine fails to add any survival benefit for this disease (www.cancer.gov). Though the incidence of pancreatic cancer is found to be higher in developed countries, the aggressive biology of the cancer, its high rate of recurrence and chemo-resistance make it a formidable disease in all parts of the globe. Hepatocellular carcinoma (HCC) or liver cancer, on the other hand affects almost 750,000 people world wide with 84% of the cases coming from underdeveloped or developing countries
RESULTS: Our studies show that Minnelide, a water soluble pro-drug of triptolide (active compound from a chinese herb) is very effective against a number of malignant diseases.
CONCLUSION: The current study discusses the efficacy of this compound in pancreatic and liver cancer.
Copyright © 2015 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal models; Hepatocellular carcinoma; Minnelide; Pancreatic cancer; Translational study; Triptolide

Mesh:

Substances:

Year:  2015        PMID: 26122306      PMCID: PMC4515388          DOI: 10.1016/j.pan.2015.05.472

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  21 in total

Review 1.  Hepatocellular carcinoma: present status and future prospects.

Authors:  Josep M Llovet; Michel Beaugrand
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

2.  Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.

Authors:  Osama A Alsaied; Veena Sangwan; Sulagna Banerjee; Tara C Krosch; Rohit Chugh; Ashok Saluja; Selwyn M Vickers; Eric H Jensen
Journal:  Surgery       Date:  2014-06-19       Impact factor: 3.982

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 4.  The epidemiology of pancreatitis and pancreatic cancer.

Authors:  Dhiraj Yadav; Albert B Lowenfels
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

Review 5.  Sorafenib for treatment of hepatocellular carcinoma: a systematic review.

Authors:  Bingru Xie; David H Wang; Stuart Jon Spechler
Journal:  Dig Dis Sci       Date:  2012-03-27       Impact factor: 3.199

Review 6.  Current status of molecular markers for early detection of sporadic pancreatic cancer.

Authors:  Subhankar Chakraborty; Michael J Baine; Aaron R Sasson; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2010-10-01

Review 7.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.

Authors:  Muhammad Wasif Saif
Journal:  JOP       Date:  2008-07-10

10.  Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.

Authors:  Susanne Gahr; Till Wissniowski; Steffen Zopf; Deike Strobel; Anette Pustowka; Matthias Ocker
Journal:  J Cancer       Date:  2012-04-09       Impact factor: 4.207

View more
  13 in total

Review 1.  The Mitochondrion as an Emerging Therapeutic Target in Cancer.

Authors:  Katherine G Roth; Isa Mambetsariev; Prakash Kulkarni; Ravi Salgia
Journal:  Trends Mol Med       Date:  2019-07-18       Impact factor: 11.951

2.  Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression.

Authors:  Patricia Dauer; Xianda Zhao; Vineet K Gupta; Nikita Sharma; Kousik Kesh; Prisca Gnamlin; Vikas Dudeja; Selwyn M Vickers; Sulagna Banerjee; Ashok Saluja
Journal:  Cancer Res       Date:  2017-12-19       Impact factor: 12.701

Review 3.  Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials.

Authors:  Zhiyi Zhang; Jie Song; Cao Xie; Jun Pan; Weiyue Lu; Min Liu
Journal:  AAPS J       Date:  2021-02-12       Impact factor: 4.009

4.  Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.

Authors:  Yulin Ren; A Douglas Kinghorn
Journal:  J Med Chem       Date:  2020-12-08       Impact factor: 7.446

5.  Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats.

Authors:  Jing Yang; Lixin Sun; Lu Wang; Hozeifa M Hassan; Xuan Wang; Phillip B Hylemon; Tao Wang; Huiping Zhou; Luyong Zhang; Zhenzhou Jiang
Journal:  Front Pharmacol       Date:  2017-05-09       Impact factor: 5.810

6.  Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia.

Authors:  Bhuwan Giri; Vineet K Gupta; Brianna Yaffe; Shrey Modi; Pooja Roy; Vrishketan Sethi; Shweta P Lavania; Selwyn M Vickers; Vikas Dudeja; Sulagna Banerjee; Justin Watts; Ashok Saluja
Journal:  J Transl Med       Date:  2019-05-20       Impact factor: 5.531

7.  1H NMR-Based Metabolomics Reveals the Antitumor Mechanisms of Triptolide in BALB/c Mice Bearing CT26 Tumors.

Authors:  Cheng Li; Zhongfeng Li; Tianjiao Zhang; Peihuang Wei; Nuo Li; Wei Zhang; Xia Ding; Jian Li
Journal:  Front Pharmacol       Date:  2019-10-11       Impact factor: 5.810

8.  Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts.

Authors:  Pawan Noel; Shaimaa Hussein; Serina Ng; Corina E Antal; Wei Lin; Emily Rodela; Priscilla Delgado; Sanna Naveed; Michael Downes; Yin Lin; Ronald M Evans; Daniel D Von Hoff; Haiyong Han
Journal:  Oncogenesis       Date:  2020-11-09       Impact factor: 7.485

9.  Triptolide inhibits Wnt signaling in NSCLC through upregulation of multiple Wnt inhibitory factors via epigenetic modifications to Histone H3.

Authors:  Isaac Nardi; Theresa Reno; Xinwei Yun; Terra Sztain; Jami Wang; Huifang Dai; Li Zheng; Binghui Shen; Jae Kim; Dan Raz
Journal:  Int J Cancer       Date:  2018-09-19       Impact factor: 7.396

Review 10.  Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy.

Authors:  Xiao-Xin Sun; Yanping Li; Rosalie C Sears; Mu-Shui Dai
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.